A third‐generation EGFR TKI osimertinib was approved for patients with EGFR T790M‐positive metastatic NSCLC progressing after the failure of first‐ or second‐generation EGFR TKIs,5 but treatments for those with T790M‐negative acquired resistance are extremely limited. Here, EGFR is linked to non-small cell lung carcinoma.